Panbela Therapeutics Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Waconia MN United States (2011)

Organization Overview

First Clinical Trial
2022
NCT05254171
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Panbela Therapeutics | Panbela Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (5)

Key: Panbela Therapeutics (3) Acquired (2)

diethyl dihydroxyhomospermine (1 trial)

eflornithine (ornidyl) (7 trials)

gemcitabine (gemzar) (1 trial)

paclitaxel (taxol) (1 trial)

sulindac (clinoril) (4 trials)

Drugs in Phase 2 Trials (1)

Key: Panbela Therapeutics (0) Acquired (1)

dl-2-(difluoromethyl) ornithine (1 trial)

Drugs in Phase 1 Trials (1)

Key: Panbela Therapeutics (0) Acquired (1)

etoposide (vepesid) (1 trial)

Indications

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 7